MAP2K7 and malignant peripheral nerve sheath tumor: We turned our attention to a validated therapeutic model: the Nf1+/−/Tp53+/−/Suz12+/− model of MPNST, which responds to a molecularly targeted combination of an MEK inhibitor (PD901) and a bromodomain inhibitor (JQ1) (De Raedt et al., 2014).